Longeveron shares plunge after Phase 2b stem-cell trial misses endpoint
Longeveron said its Phase 2b trial of a stem-cell therapy for a pediatric heart condition failed to meet its primary endpoint, sending shares down about 60% to $2.65 in after-hours trading.
Longeveron said it has started exploring options to maximize shareholder value after a Phase 2b trial of a stem-cell therapy for a heart condition in children failed to meet its primary endpoint. 65, in after-hours trading on Wednesday.